Instrumenti kvaliteta života specifični za dermatologiju, sve češće se primenjuju u istraživanju kod pacijenata sa kožnim bolestima. CIlj je ispitati odnos ocena kvaliteta života dobijenih primenom dva za dermatologiju specifična instrumenta. Istraživanjem je obuhvaćeno 62 ispitanika sa kožnim bolestima, kod kojih je kvalitet života ocenjen primenom instrumenata specifičnih za dermatologiju (tj. Dermatology Life Quality Index-DLQI i Skindex-16), namenjenih upotrebi kod svih kožnih bolesti. Ukupni skorovi DLQI i Skindex-16 nalazili su se u jakoj korelaciji (r=0.87; p<0.001). Postojale su i statistički značajne korelacije ukupnog skora DLQI sa skorovima za podskale simptomi, emocije i funkcionisanje iz Skindex-16 instrumenta (r=0.53, r=0.77 i r=0.86, redom). Ukupan skor Skindex-16 nije bio u korelaciji sa skorom za podskalu tretman iz DLQI-a, međutim, bio je u korelaciji sa skorovima za podskale simptomi i osećanja, dnevne aktivnosti, slobodne aktivnosti, rad ili škola i lični odnosi iz DLQI-a (r=0.67, r=0.80, r=0.66, r=0.62 i r=0.68, redom). Dva instrumenta specifična za dermatologiju (npr. DLQI i Skindex-16), ukoliko se zajedno primenjuju, mogu pružiti komplementarne podatke pri ocenjivanju kvaliteta života pacijenata sa kožnim bolestima.

In diabetics fungal skin infections are reported to be related to greatly disturbed metabolism. In order to get better insight into the association between diabetes mellitus and fungal skin infections, we started our study with the aim to assess the effect of metabolic regulation on the incidence of fungal skin infections is diabetics. The obtained results of our study show that in patient with metabolically poorly regulated primary disease i.e. diabetes the incidence of the fungal skin infections is highest (36.0%), its incidence is lower in patients with metabolically satisfactorily regulated diabetes (29.5%) and lowest in those with well regulated diabetes (18.8%), witch is statistically significant difference (p=0.045).

Metformin is an anti-hyperglycemic agent used for the treatment of type 2 diabetes mellitus. Biguanides lower blood glucose levels primarily by decreasing the amount of glucose produced by the liver. Metformin also helps to lower blood glucose levels by making muscle tissue more sensitive to insulin so glucose can be absorbe. The purpose of the study was to establish the effect of metformin on insulin secretion in obese patients with newly diagnosed diabetes mellitus type 2. We included 40 patients with Type-2 Diabetes Mellitus, who were treated on Department for Internal Disease in Hospital King Milutin Laplje Selo. Patients included in the study were newly diagnosed with diabetes mellitus type 2, glycemia < 12 mmol/L, and hed the Body Mass Index >30 kg/m2. They were treated with metformin, 1000 mg/day. Insulin sensitivity was determined by HOMA IR, insulin secretion by HOMA, lipid status by spectrophotometry. After six months of treatment blood biochemistry tested again. BMI was also established. Metformin significantly lowered BMI (BMI before therapy 31.02 kg/m2, after treatment 28.7 kg/m2) (both p<0,001 vs baseline) waist circumference mean value 98±0.55 cm-93,12 cm. (p<0,001) During the therapy the glycaemia decreased from 11.7 mmol - 6,78 mmol/l, insulinemia mean value 20.141 mlU/l -13.691, HOMA IR elevated in all patients. Among the cholesterol fractions, most significant results were obtained in LDL cholesterol. Mean LDL cholesterol levels 4.51± 2.02 mmol/L. Mean cholesterol level 6.98±2.31 mmol/L. HDL levels -1.32 mmol/L. Serum triglycerides was (mean) 2.63±1.32mmol/L. After six months therapy Metformin produces beneficial changes in lipid states. Metformin may be the first therapeutic option in the diabetes mellitus type 2 with overweight or obesity. Metformin produces beneficial changes in glycemia control, and moderated in weight, lipids and insulinemia. 

The objective of this study that included 34 patients with psoriasis was to assess the reliability of the disease severity measures (i.e. Psoriasis Area and Severity Index - PASI) and the reliability of the health related quality of life measures (i.e. EuroQol EQ-5D Quality of Life Scale - EQ-5D, Dermatology Life Quality Index - DLQI and Psoriasis Disability Index -PDI). High interobserver correlation reliability and good test-retest reliability of PASI scores, as well as good test-retest reliability of EQ-5D, DLQI and PDI scores were achieved. Correlation coefficients between the test and retest scores on DLQI and PDI were higher than those on the dimensions and on EQ-VAS in EQ-5D. Disease severity scores given by PASI and the quality of lify scores given by EQ-5D, DLQI and PDI offered the reliable assessment of both the psoriasis severity and the quality of life of the people with psoriasis.

Diabetes mellitus is a typical example for connection betwen sickness of internal organs and the skin. The ratio betwen glycose level in a gram of skin and the amount of glycose in a mililiter of blood is higher in diabetes mellitus then normal. This implies that insulin regulates intracelular distribution of glycose in the skin. It is recessary for the keratinocyt growth and diferentiation, healing of wounds, but also for the fibroblast functioning in the derm. In diabetes mellitus acidofil is lowered, and glycolised colagen is increased, and fibroblasts in the extra produce fibronectin. Skin and visible mucosys infections caused by candida albicans in diabetes patients belong to the group of deseases that could be a consequence of a disbalanced metabolism. They are seen frequently, but not patognomic for these patients, becuse they are also possible in people whose metabolism is normal. Badly controlled or undiagnosed dibetes mellitus is often coupled with candida induced skin deseases. Sometimes candida infections are the first sign of diabetes. Dermatologist is often in position to discover the disease on the basis of skin symptoms, which gives possibility for regulation of the sickness on time and avoid complications. It is known that complications develop slower when diabetes is regulated. Skin alterations in candidiasys and its connection with diabetes are described briefly, with an attempl to explain patogenesys of their apearence.

A chronic hyperglicemia with diabetes leads to damage, disfunction and physiology disorders in various organs and tissues so the skin changes are occuring frequently. They are serious and are early discovered. The importance of knowing the bacterial skin infection with diabetes patient is in the fact that sometimes they can be markers and be preceded of the manifestation of the diabetes during the years i.e. in the prevention of the complications even though the glucose tolerance is limited. Then, any increase of the glucose level should be considered patological. Acute and chronic bacterial skin infections can change the regulation of diabetes which may lead to worse metabolic regulation with diabetes patients. The bacterial skin infections belong to the infection group that according to the clinical experience more frequently appear
in diabetes. But a close connection with diabetes is not proved. This study aims to point out the bacterial skin infections with diabetes patients. The results of our study indicates that bacterial skin infections are more frequently represented with diabetes patients (11.0%) than with the persons without Diabetes mellitus (4.8%).